FIGURE 1.

FGF9 does not affect the proliferation or migration of Renca cells. A, SYBRSafe-stained agarose gel depicting RT-PCR transcripts in Renca cells (R) and primary mouse dermal fibroblasts (F) for FGF receptors. B, Western blots of phosphorylated and total ERK1/2 in mouse dermal fibroblasts, mouse embryonic fibroblasts, 10T1/2 cells, and Renca cells subjected to 50 ng/ml of recombinant FGF9 or vehicle for 10 min. C, Western blots of phosphorylated and total ERK1/2 in Renca cells subjected to 50 ng/ml of recombinant FGF2 or FGF9 for 10 min. D, left, population growth of Renca cells in RPMI 1640 incubated with FGF9 (50 ng/ml) and 0.5% FBS, with PBS and 0.5% FBS, or with 10% FBS. p < 0.001. Middle, population growth of Renca cells transduced with adenovirus containing cDNA encoding either human FGF9 or GFP and cultured in medium with 0.5 or 10% FBS. Cell numbers were quantified in triplicate wells over 7 days. Western blots of cells harvested 48 h after transduction are shown. Right, proliferation response to FGF9 of Renca cells, dermal fibroblasts, and 10T1/2 cells, relative to that of vehicle. *, p < 0.001 versus Renca cells; †, p = 0.004 versus Renca cells. E, apoptosis of Renca cells and mouse dermal fibroblasts in 0.5% FBS-containing medium for 2 days, as assessed by TUNEL assay. *, p < 0.001 versus vehicle. F, migration speed of Renca cells transduced with adenovirus encoding GFP or FGF9 (left) and of Renca cells and mouse dermal fibroblasts in vehicle or recombinant FGF9 (50 ng/ml) (right), as assessed by time-lapse microscopy. *, p = 0.036 versus vehicle.